{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:05:32Z","timestamp":1784246732668,"version":"3.55.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"AstraZeneca Vietnam"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16085-0","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T23:32:42Z","timestamp":1784244762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-generation sequencing-based characterization of BRCA1\/2 variants across multiple tumor types in Vietnamese patients"],"prefix":"10.1186","volume":"26","author":[{"given":"Hong-Thanh","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh-Duc","family":"Vu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinh-Dung","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong-Nhung","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van-Quy","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh-Trang Ngoc","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinh-Tuan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuoc-Huy","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thi-Oanh","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van-Hung","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thu-Huong Thi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sy-Tung","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy-Duong","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanh-Ha Thi","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viet-Nhan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"5","key":"16085_CR1","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.ajpath.2011.01.050","volume":"178","author":"AA Arbini","year":"2011","unstructured":"Arbini AA, Greco M, Yao JL, et al. Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer. Am J Pathol. 2011;178(5):2367\u201376. https:\/\/doi.org\/10.1016\/j.ajpath.2011.01.050.","journal-title":"Am J Pathol"},{"issue":"5","key":"16085_CR2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1200\/JCO.23.02225","volume":"42","author":"I Bedrosian","year":"2024","unstructured":"Bedrosian I, Somerfield MR, Achatz MI, et al. Germline testing in patients with breast cancer: ASCO\u2013Society of Surgical Oncology guideline. J Clin Oncol. 2024;42(5):584\u2013604. https:\/\/doi.org\/10.1200\/JCO.23.02225.","journal-title":"J Clin Oncol"},{"issue":"22","key":"16085_CR3","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"Jd Bono","year":"2020","unstructured":"Bono Jd, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091\u2013102. https:\/\/doi.org\/10.1056\/NEJMoa1911440.","journal-title":"N Engl J Med"},{"issue":"14","key":"16085_CR4","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","volume":"31","author":"E Castro","year":"2013","unstructured":"Castro E, Goh C, Olmos D, et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013;31(14):1748\u201357. https:\/\/doi.org\/10.1200\/JCO.2012.43.1882.","journal-title":"J Clin Oncol"},{"issue":"9","key":"16085_CR5","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1001\/jamaoncol.2024.2185","volume":"10","author":"HH Cheng","year":"2024","unstructured":"Cheng HH, Shevach JW, Castro E, et al. BRCA1, BRCA2 and associated cancer risks and management for males: a review. JAMA Oncol. 2024;10(9):1272\u201381. https:\/\/doi.org\/10.1001\/jamaoncol.2024.2185.","journal-title":"JAMA Oncol"},{"issue":"1","key":"16085_CR6","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10549-011-1544-9","volume":"132","author":"K De Leeneer","year":"2012","unstructured":"De Leeneer K, Coene I, Crombez B, et al. Prevalence of BRCA1\/2 mutations in sporadic breast\/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: Implications for genetic testing. Breast Cancer Res Treat. 2012;132(1):87\u201395. https:\/\/doi.org\/10.1007\/s10549-011-1544-9.","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"16085_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102453","volume":"14","author":"N Devico Marciano","year":"2022","unstructured":"Devico Marciano N, Kroening G, Dayyani F, et al. BRCA-mutated pancreatic cancer: From discovery to novel treatment paradigms. Cancers. 2022;14(10):2453. https:\/\/doi.org\/10.3390\/cancers14102453.","journal-title":"Cancers"},{"issue":"3","key":"16085_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1590\/S1415-47572009005000049","volume":"32","author":"IP Ewald","year":"2009","unstructured":"Ewald IP, Ribeiro PLI, Palmero EI, Cossio SL, Giugliani R, Ashton-Prolla P. Genomic rearrangements in BRCA1 and BRCA2: a literature review. Genet Mol Biol. 2009;32(3):437\u201346. https:\/\/doi.org\/10.1590\/S1415-47572009005000049.","journal-title":"Genet Mol Biol"},{"issue":"15","key":"16085_CR9","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1200\/JCO.20.01200","volume":"39","author":"PA Fasching","year":"2021","unstructured":"Fasching PA, Yadav S, Hu C, et al. Mutations in BRCA1\/2 and other panel genes in patients with metastatic breast cancer \u2014Association with patient and disease characteristics and effect on prognosis. J Clin Oncol. 2021;39(15):1619\u201330. https:\/\/doi.org\/10.1200\/JCO.20.01200.","journal-title":"J Clin Oncol"},{"issue":"1","key":"16085_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1399-0004.2010.01545.x","volume":"80","author":"OM Ginsburg","year":"2011","unstructured":"Ginsburg OM, Dinh NV, To TV, et al. Family history, BRCA mutations and breast cancer in Vietnamese women. Clin Genet. 2011;80(1):89\u201392. https:\/\/doi.org\/10.1111\/j.1399-0004.2010.01545.x.","journal-title":"Clin Genet"},{"issue":"9","key":"16085_CR11","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.7150\/jca.30410","volume":"10","author":"I Gorodetska","year":"2019","unstructured":"Gorodetska I, Kozeretska I, Dubrovska A. BRCA genes: the role in genome stability, cancer stemness and therapy resistance. J Cancer. 2019;10(9):2109\u201327. https:\/\/doi.org\/10.7150\/jca.30410.","journal-title":"J Cancer"},{"key":"16085_CR12","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1200\/GO.21.00051","volume":"7","author":"S Gupta","year":"2021","unstructured":"Gupta S, Rajappa S, Advani S, et al. Prevalence of BRCA1 and BRCA2 mutations among patients with ovarian, primary peritoneal, and fallopian tube cancer in India: a multicenter cross-sectional study. JCO Glob Oncol. 2021;7:849\u201361. https:\/\/doi.org\/10.1200\/GO.21.00051.","journal-title":"JCO Glob Oncol"},{"key":"16085_CR13","doi-asserted-by":"publisher","unstructured":"Ha Vu, Phu Nd, Khuong LT, et al. Recurrent BRCA1 mutation, but no BRCA2 mutation, in Vietnamese patients with ovarian carcinoma detected with next generation sequencing. Asian Pac J Cancer Prev\u202f: APJCP. 2020;21(8). https:\/\/doi.org\/10.31557\/APJCP.2020.21.8.2331.","DOI":"10.31557\/APJCP.2020.21.8.2331"},{"key":"16085_CR14","doi-asserted-by":"publisher","unstructured":"Hu C, SN Hart, R Gnanaolivu, et al. A population-based study of genes previously implicated in breast cancer. New England J Med, ahead of print, February 4. World. 2021. https:\/\/doi.org\/10.1056\/NEJMoa2005936.","DOI":"10.1056\/NEJMoa2005936"},{"issue":"1","key":"16085_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4098-y","volume":"18","author":"M Ibrahim","year":"2018","unstructured":"Ibrahim M, Yadav S, Ogunleye F, Zakalik D. Male BRCA mutation carriers: clinical characteristics and cancer spectrum. BMC Cancer. 2018;18(1):179. https:\/\/doi.org\/10.1186\/s12885-018-4098-y.","journal-title":"BMC Cancer"},{"issue":"5","key":"16085_CR16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1136\/jmg-2023-109694","volume":"61","author":"G Innella","year":"2024","unstructured":"Innella G, Ferrari S, Miccoli S, et al. Clinical implications of VUS reclassification in a single-centre series from application of ACMG\/AMP classification rules specified for BRCA1\/2. J Med Genet. 2024;61(5):483\u20139. https:\/\/doi.org\/10.1136\/jmg-2023-109694.","journal-title":"J Med Genet"},{"issue":"21","key":"16085_CR17","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1002\/cncr.27556","volume":"118","author":"T Judkins","year":"2012","unstructured":"Judkins T, Rosenthal E, Arnell C, et al. Clinical significance of large rearrangements in BRCA1 and BRCA2. Cancer. 2012;118(21):5210\u20136. https:\/\/doi.org\/10.1002\/cncr.27556.","journal-title":"Cancer"},{"key":"16085_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrrev.2025.108549","volume":"796","author":"S Khan","year":"2025","unstructured":"Khan S, Burney IA, Nasir M, et al. Spectrum of BRCA1\/2 pathogenic variants in Southern and Western Asia-a systematic review. Mutat Res Rev Mutat Res. 2025;796:108549. https:\/\/doi.org\/10.1016\/j.mrrev.2025.108549.","journal-title":"Mutat Res Rev Mutat Res"},{"issue":"3","key":"16085_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/BF01366952","volume":"122","author":"AG Knudson","year":"1996","unstructured":"Knudson AG. Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol. 1996;122(3):135\u201340. https:\/\/doi.org\/10.1007\/BF01366952.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"16085_CR20","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1001\/jama.2020.0229","volume":"323","author":"AW Kurian","year":"2020","unstructured":"Kurian AW, Bernhisel R, Larson K, et al. Prevalence of pathogenic variants in cancer susceptibility genes among women with postmenopausal breast cancer. JAMA. 2020;323(10):995\u20137. https:\/\/doi.org\/10.1001\/jama.2020.0229.","journal-title":"JAMA"},{"issue":"8","key":"16085_CR21","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamaoncol.2018.0644","volume":"4","author":"AW Kurian","year":"2018","unstructured":"Kurian AW, Ward KC, Hamilton AS, et al. Uptake, results, and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer. JAMA Oncol. 2018;4(8):1066\u201372. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0644.","journal-title":"JAMA Oncol"},{"issue":"15","key":"16085_CR22","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1200\/JCO.18.01854","volume":"37","author":"AW Kurian","year":"2019","unstructured":"Kurian AW, Ward KC, Howlader N, et al. Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J Clin Oncol. 2019;37(15):1305\u201315. https:\/\/doi.org\/10.1200\/JCO.18.01854.","journal-title":"J Clin Oncol"},{"issue":"3","key":"16085_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.annonc.2022.12.003","volume":"34","author":"Z Kuzbari","year":"2023","unstructured":"Kuzbari Z, Bandlamudi C, Loveday C, et al. Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations. Ann Oncol. 2023;34(3):215\u201327. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.003.","journal-title":"Ann Oncol"},{"issue":"2","key":"16085_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/genes13020268","volume":"13","author":"TN Le","year":"2022","unstructured":"Le TN, Tran VK, Nguyen TT, et al. BRCA1\/2 mutations in Vietnamese patients with hereditary breast and ovarian cancer syndrome. Genes (Basel). 2022;13(2):268. https:\/\/doi.org\/10.3390\/genes13020268.","journal-title":"Genes (Basel)"},{"issue":"1","key":"16085_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer. J Mol Diagn. 2017;19(1):4\u201323. https:\/\/doi.org\/10.1016\/j.jmoldx.2016.10.002.","journal-title":"J Mol Diagn"},{"key":"16085_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.718871","volume":"11","author":"S Li","year":"2021","unstructured":"Li S, Tao Li, Dai H, et al. BRCA1 versus BRCA2 and PARP inhibitors efficacy in solid tumors: A meta-analysis of randomized controlled trials. Front Oncol. 2021;11:718871. https:\/\/doi.org\/10.3389\/fonc.2021.718871.","journal-title":"Front Oncol"},{"issue":"14","key":"16085_CR27","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1200\/JCO.21.02112","volume":"40","author":"S Li","year":"2022","unstructured":"Li S, Silvestri V, Leslie G, et al. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. J Clin Oncol. 2022;40(14):1529\u201341. https:\/\/doi.org\/10.1200\/JCO.21.02112.","journal-title":"J Clin Oncol"},{"issue":"8","key":"16085_CR28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753\u201363. https:\/\/doi.org\/10.1056\/NEJMoa1802905.","journal-title":"N Engl J Med"},{"issue":"4","key":"16085_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104533","volume":"10","author":"C Marchetti","year":"2025","unstructured":"Marchetti C, Fagotti A, Fruscio R, et al. Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1\/2 mutation type and site: a multicenter real-world study. ESMO Open. 2025;10(4):104533. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104533.","journal-title":"ESMO Open"},{"issue":"1","key":"16085_CR30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1470-2045(19)30684-9","volume":"21","author":"J Mateo","year":"2020","unstructured":"Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, Phase 2 trial. Lancet Oncol. 2020;21(1):162\u201374. https:\/\/doi.org\/10.1016\/S1470-2045(19)30684-9.","journal-title":"Lancet Oncol"},{"key":"16085_CR31","unstructured":"Nature Index. Breast Cancer Association Consortium (BCAC). (n.d.). https:\/\/www.nature.com\/nature-index\/institution-outputs\/United%20Kingdom%20%28UK%29\/Breast%20Cancer%20Association%20Consortium%20%28BCAC%29\/537af007140ba0a733000004. Accessed 10 Oct 2025."},{"issue":"3","key":"16085_CR32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1089\/gtmb.2008.0155","volume":"13","author":"AMW van den Ouweland","year":"2009","unstructured":"van den Ouweland AMW, Dinjens WNM, Dorssers LCJ, et al. Deletion of exons 1a-2 of BRCA1: a rather frequent pathogenic abnormality. Genet Test Mol Biomarkers. 2009;13(3):399\u2013406. https:\/\/doi.org\/10.1089\/gtmb.2008.0155.","journal-title":"Genet Test Mol Biomarkers"},{"issue":"1","key":"16085_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00559-0","volume":"8","author":"WK Park","year":"2024","unstructured":"Park WK, Chung SY, Jung YJ, et al. Long-term oncologic outcomes of unselected triple-negative breast cancer patients according to BRCA1\/2 mutations. Npj Precis Oncol. 2024;8(1):96. https:\/\/doi.org\/10.1038\/s41698-024-00559-0.","journal-title":"Npj Precis Oncol"},{"issue":"5","key":"16085_CR34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/GIM.0b013e3181d38f2f","volume":"12","author":"N Petrucelli","year":"2010","unstructured":"Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med. 2010;12(5):5. https:\/\/doi.org\/10.1097\/GIM.0b013e3181d38f2f.","journal-title":"Genet Med"},{"key":"16085_CR35","unstructured":"Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. In GeneReviews\u00ae. University of Washington, Seattle. 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1247\/."},{"issue":"2","key":"16085_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1515\/oncologie-2023-0556","volume":"26","author":"PC Pham","year":"2023","unstructured":"Pham PC, Van Pham T, Dinh LD, et al. BRCA mutation in Vietnamese prostate cancer patients: a mixed cross-sectional study and case series. Oncologie. 2023;26(2):247\u201356. https:\/\/doi.org\/10.1515\/oncologie-2023-0556.","journal-title":"Oncologie"},{"issue":"12","key":"16085_CR37","doi-asserted-by":"publisher","first-page":"3624","DOI":"10.1007\/s43032-024-01666-w","volume":"31","author":"P Pourmasoumi","year":"2024","unstructured":"Pourmasoumi P, Moradi A, Bayat M. BRCA1\/2 mutations and breast\/ovarian cancer risk: a new insights review. Reprod Sci. 2024;31(12):3624\u201334. https:\/\/doi.org\/10.1007\/s43032-024-01666-w.","journal-title":"Reprod Sci"},{"issue":"4","key":"16085_CR38","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016600","volume":"7","author":"R Prakash","year":"2015","unstructured":"Prakash R, Zhang Yu, Feng W, Jasin M. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol. 2015;7(4):a016600. https:\/\/doi.org\/10.1101\/cshperspect.a016600.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"March","key":"16085_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1133472","volume":"11","author":"A Ragupathi","year":"2023","unstructured":"Ragupathi A, Singh M, Perez AM, Zhang D. Targeting the BRCA1\/2 deficient cancer with PARP inhibitors: clinical outcomes and mechanistic insights. Front Cell Dev Biol. 2023;11(March):1133472. https:\/\/doi.org\/10.3389\/fcell.2023.1133472.","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"16085_CR40","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41585-022-00680-4","volume":"20","author":"P Rajwa","year":"2023","unstructured":"Rajwa P, Quhal F, Pradere B, et al. Prostate cancer risk, screening and management in patients with germline BRCA1\/2 mutations. Nat Rev Urol. 2023;20(4):205\u201316. https:\/\/doi.org\/10.1038\/s41585-022-00680-4.","journal-title":"Nat Rev Urol"},{"issue":"5","key":"16085_CR41","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324. https:\/\/doi.org\/10.1038\/gim.2015.30.","journal-title":"Genet Med"},{"issue":"6","key":"16085_CR42","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1706450.","journal-title":"N Engl J Med"},{"issue":"4","key":"16085_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040760","volume":"13","author":"EJ Saunders","year":"2021","unstructured":"Saunders EJ, Kote-Jarai Z, Eeles RA. Identification of germline genetic variants that increase prostate cancer risk and influence development of aggressive disease. Cancers. 2021;13(4):760. https:\/\/doi.org\/10.3390\/cancers13040760.","journal-title":"Cancers"},{"issue":"2","key":"16085_CR44","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/cas.14242","volume":"111","author":"Di Shao","year":"2020","unstructured":"Shao Di, Cheng S, Guo F, et al. Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high-risk Chinese individuals. Cancer Sci. 2020;111(2):647\u201357. https:\/\/doi.org\/10.1111\/cas.14242.","journal-title":"Cancer Sci"},{"issue":"8","key":"16085_CR45","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/gim.2015.166","volume":"18","author":"LR Susswein","year":"2016","unstructured":"Susswein LR, Marshall ML, Nusbaum R, et al. Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med. 2016;18(8):823\u201332. https:\/\/doi.org\/10.1038\/gim.2015.166.","journal-title":"Genet Med"},{"issue":"10","key":"16085_CR46","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.28977","volume":"4","author":"K Taparra","year":"2021","unstructured":"Taparra K, Fukui J, Killeen J, Sumida K, Loo LWM, Hernandez BY. Racial and ethnic disparities in rates of invasive second breast cancer among women with ductal carcinoma in situ in Hawai\u02bbi. JAMA Netw Open. 2021;4(10):e2128977. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.28977.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"16085_CR47","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/gim.2017.210","volume":"20","author":"SV Tavtigian","year":"2018","unstructured":"Tavtigian SV, Greenblatt MS, Harrison SM, et al. Modeling the ACMG\/AMP variant classification guidelines as a Bayesian classification framework. Genet Med. 2018;20(9):1054\u201360. https:\/\/doi.org\/10.1038\/gim.2017.210.","journal-title":"Genet Med"},{"key":"16085_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104949","volume":"216","author":"MG Tibiletti","year":"2025","unstructured":"Tibiletti MG, Carnevali I, Cimadamore A, et al. Practical tricks and recommendations on BRCA1\/2 testing in prostate cancer: From therapy to cancer prevention. Crit Rev Oncol Hematol. 2025;216:104949. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104949.","journal-title":"Crit Rev Oncol Hematol"},{"key":"16085_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01096-9","volume":"15","author":"J Tittmann","year":"2024","unstructured":"Tittmann J, \u00c1gh T, Erd\u0151si D, et al. Breast cancer stage and molecular subtype distribution: real-world insights from a regional oncological center in Hungary. Discov Oncol. 2024;15:240. https:\/\/doi.org\/10.1007\/s12672-024-01096-9.","journal-title":"Discov Oncol"},{"key":"16085_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.789659","volume":"11","author":"VT Tran","year":"2021","unstructured":"Tran VT, Nguyen ST, Pham XD, et al. Pathogenic variant profile of hereditary cancer syndromes in a Vietnamese cohort. Front Oncol. 2021;11:789659. https:\/\/doi.org\/10.3389\/fonc.2021.789659.","journal-title":"Front Oncol"},{"issue":"4","key":"16085_CR51","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41391-023-00676-0","volume":"27","author":"H Tuffaha","year":"2024","unstructured":"Tuffaha H, Edmunds K, Fairbairn D, et al. Guidelines for genetic testing in prostate cancer: a scoping review. Prostate Cancer Prostatic Dis. 2024;27(4):594\u2013603. https:\/\/doi.org\/10.1038\/s41391-023-00676-0.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"21","key":"16085_CR52","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1200\/JCO.24.00662","volume":"42","author":"N Tung","year":"2024","unstructured":"Tung N, Ricker C, Messersmith H, et al. Selection of germline genetic testing panels in patients with cancer: ASCO guideline. J Clin Oncol. 2024;42(21):2599\u2013615. https:\/\/doi.org\/10.1200\/JCO.24.00662.","journal-title":"J Clin Oncol"},{"issue":"7","key":"16085_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073753","volume":"22","author":"MT Vietri","year":"2021","unstructured":"Vietri MT, D\u2019Elia G, Caliendo G, et al. Hereditary prostate cancer: genes related, target therapy and prevention. Int J Mol Sci. 2021;22(7):3753. https:\/\/doi.org\/10.3390\/ijms22073753.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"16085_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s44276-024-00100-7","volume":"2","author":"DN Vinh","year":"2024","unstructured":"Vinh DN, Nguyen TTN, Tran T-A, et al. Breast cancer risk assessment based on susceptibility genes and polygenic risk score in Vietnamese women. BJC Rep. 2024;2(1):80. https:\/\/doi.org\/10.1038\/s44276-024-00100-7.","journal-title":"BJC Rep"},{"issue":"1","key":"16085_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s44276-025-00122-9","volume":"3","author":"Y-W Wang","year":"2025","unstructured":"Wang Y-W, Allen I, Funingana G, Tischkowitz M, Joko-Fru YW. Predictive biomarkers for the efficacy of PARP inhibitors in ovarian cancer: an updated systematic review. BJC Rep. 2025;3(1):14. https:\/\/doi.org\/10.1038\/s44276-025-00122-9.","journal-title":"BJC Rep"},{"key":"16085_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.844575","volume":"13","author":"H Werner","year":"2022","unstructured":"Werner H. BRCA1: an endocrine and metabolic regulator. Front Endocrinol. 2022;13:844575. https:\/\/doi.org\/10.3389\/fendo.2022.844575.","journal-title":"Front Endocrinol"},{"issue":"13","key":"16085_CR57","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1200\/JCO.19.02190","volume":"38","author":"S Yadav","year":"2020","unstructured":"Yadav S, Hu C, Hart SN, et al. Evaluation of germline genetic testing criteria in a hospital-based series of women with breast cancer. J Clin Oncol. 2020;38(13):1409\u201318. https:\/\/doi.org\/10.1200\/JCO.19.02190.","journal-title":"J Clin Oncol"},{"issue":"6","key":"16085_CR58","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s12282-020-01148-2","volume":"28","author":"R Yoshida","year":"2021","unstructured":"Yoshida R. Hereditary Breast and Ovarian Cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. Breast Cancer. 2021;28(6):1167\u201380. https:\/\/doi.org\/10.1007\/s12282-020-01148-2.","journal-title":"Breast Cancer"},{"issue":"6","key":"16085_CR59","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1200\/JCO-24-02608","volume":"43","author":"EY Yu","year":"2025","unstructured":"Yu EY, Rumble RB, Agarwal N, et al. Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline. J Clin Oncol. 2025;43(6):748\u201358. https:\/\/doi.org\/10.1200\/JCO-24-02608.","journal-title":"J Clin Oncol"},{"issue":"July","key":"16085_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102410","volume":"57","author":"T Zhou","year":"2025","unstructured":"Zhou T, Zhang J. Therapeutic advances and application of PARP inhibitors in breast cancer. Transl Oncol. 2025;57(July):102410. https:\/\/doi.org\/10.1016\/j.tranon.2025.102410.","journal-title":"Transl Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16085-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16085-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16085-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T23:32:43Z","timestamp":1784244763000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16085-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16085"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16085-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"3 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of Ethics Council in Biomedical Research Vinmec International General Hospital Joint Stock Company\u2014VinUni University with decision number: 245\/2025\/CN\/H\u0110\u0110\u0110 VMEC. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all participants prior to their inclusion in the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data in any form (including any individual details, images, or videos). All data are presented in an aggregate or de-identified manner.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"858"}}